Abstract
There are myriad issues to consider when commercialising a biotechnological innovation. In Australia, because of market structure, the tendency for biotechnology companies to list early in their life cycles has caused problems. A fledgling venture capital market in Australia has been partly to blame. The authors outline practical, strategic considerations for bioentrepreneurs in Australasia, focusing on innovations stemming from biomedical research.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wells, N., Coady, B. & Inge, J. Spinning off, cashing up and branching out: Commercialisation considerations for bioentrepreneurs in Australasia. J Commer Biotechnol 9, 209–218 (2003). https://doi.org/10.1057/palgrave.jcb.3040030
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1057/palgrave.jcb.3040030